EMEA Widening of acceptance limit [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2012-05-02 11:28 (5153 d 23:55 ago) – Posting: # 8487
Views: 4,127

Dear hiren379
IMHO you just have to point out in the protocol that the drug has no narrow therapeutic window and that a slightly higher variability of Cmax will not raise any safety concerns. This should be sufficient to allow the ethics committee to assess the study design and the planned evaluation of the results in order to give their approval.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
136 visitors (0 registered, 136 guests [including 18 identified bots]).
Forum time: 11:24 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5